ABOS
ABOS clinical trials: Acumen Pharmaceuticals, Inc.
Every trial on ClinicalTrials.gov where Acumen Pharmaceuticals, Inc. is the lead sponsor or a listed collaborator, the trials it leads first, each labelled Lead or Collaborator. Phase, status and dates as registered.
- 3
- Trials linked
- 3
- As lead sponsor
- 0
- As collaborator
- 0
- Primary completions as lead sponsor, next 90 days
ABOS on the catalyst calendar · ABOS registry changes
| Primary completion | Trial | Company and role | Phase | Status | Enrollment | Interventions | Completion |
|---|---|---|---|---|---|---|---|
| Oct 29, 2026Actual | NCT06335173A Study to Evaluate Efficacy and Safety of Intravenous Sabirnetug in Participants With Early Alzheimer's Disease (ALTITUDE-AD)Acumen Pharmaceuticals · Alzheimer Disease | ABOSLead | Phase 2 | Active, not recruiting | Locked | Locked | Locked |
| Sep 17, 2024Actual | NCT06511570A Study Comparing the Safety, Tolerability, and Pharmacokinetics of Sabirnetug IV and Sabirnetug + rHuPH20 SC in Healthy ParticipantsAcumen Pharmaceuticals · Alzheimer Disease | ABOSLead | Phase 1 | Completed | Locked | Locked | Locked |
| Jun 12, 2023Actual | NCT04931459A Study to Evaluate the Safety, Tolerability, and Blood Levels of ACU193 in Participants With MCI or Mild ADAcumen Pharmaceuticals · Alzheimer Disease | ABOSLead | Phase 1 | Completed | Locked | Locked | Locked |
- Primary completion Oct 29, 2026ActualPhase 2NCT06335173A Study to Evaluate Efficacy and Safety of Intravenous Sabirnetug in Participants With Early Alzheimer's Disease (ALTITUDE-AD)Acumen Pharmaceuticals · Alzheimer DiseaseActive, not recruitingABOSLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Sep 17, 2024ActualPhase 1NCT06511570A Study Comparing the Safety, Tolerability, and Pharmacokinetics of Sabirnetug IV and Sabirnetug + rHuPH20 SC in Healthy ParticipantsAcumen Pharmaceuticals · Alzheimer DiseaseCompletedABOSLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jun 12, 2023ActualPhase 1NCT04931459A Study to Evaluate the Safety, Tolerability, and Blood Levels of ACU193 in Participants With MCI or Mild ADAcumen Pharmaceuticals · Alzheimer DiseaseCompletedABOSLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
Enrollment, interventions and the start and completion dates are locked on 3 rows here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.
Unlock with TrialScanner